OXIS International Inc. (OTCMKTS:OXISD) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday, September 1st.
Shares of OXIS International (OTCMKTS:OXISD) opened at 6.00 on Friday. OXIS International has a 12-month low of $3.00 and a 12-month high of $78.70. The firm’s market cap is $298.61 million.
About OXIS International
GT Biopharma, Inc, formerly OXIS International, Inc, is an immuno-oncology company. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. The Company develops drugs focused on the treatment of cancer. Its technology platform consists of bispecific and trispecific single-chain variable fragment (scFv) constructs, full-length antibodies, drug payloads, antibody-drug linkers, dual-drug payload antibody-drug conjugates (ADCs), bispecific targeted ADCs, and natural killer cell and T lymphocyte antibody directed cell-mediated cytotoxic (ADDCs) agents.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OXIS International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OXIS International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.